Indications
Diarrhea of bacterial origin.
$32.00
Active ingredient: | |
---|---|
Dosage form: | |
Indications for use: |
Diarrhea of bacterial origin.
Inside. Nifuroxazide therapy should not be continued for more than 7 days.
Adults and children over 7 years of age are prescribed 1 capsule (200 mg) 4 times a day, the daily dose is 800 mg.
For children 3-7 years of age, the drug is prescribed 1 capsule (200 mg) 3 times a day, the daily dose is 600 mg.
Children under 3 years of age. hypersensitivity to nitrofuran derivatives or other components of the drug; fructose intolerance, glucose-galactose malabsorption syndrome or sucrose and isomaltase insufficiency.
1 capsule contains:
Active substance:
nifuroxazide 200 mg,
Auxiliary substances:
sucrose-71 mg;
corn starch-68 mg;
MCC-9 mg;
magnesium stearate-2 mg,
Shell:
gelatin;
titanium dioxide;
the iron oxide dye is yellow.
Enterofuril® is a drug for the initial treatment of intestinal infections. Eliminates the cause of diarrhea-harmful microbes and bacteria. It works only in the intestinal lumen. Preserves the normal intestinal microflora. Prevents the development of bacterial complications in viral diarrhea.
1 capsule contains:
Active ingredient:
nifuroxazide 200 mg,
Auxiliary substances:
sucrose-71 mg;
corn starch-68 mg;
MCC-9 mg;
magnesium stearate-2 mg,
Shell:
gelatin;
titanium dioxide;
the iron oxide dye is yellow.
Enterofuril® is a broad-spectrum antimicrobial drug that does not have a systemic effect and is used to treat diarrhea of infectious etiology. Enterofuril®contains the Active ingredient nifuroxazide, a drug of the 5-nitrofuran derivative group. The drug has a bactericidal and bacteriostatic effect against most pathogens of acute intestinal infections. The antimicrobial effect of nifuroxazide is dose-dependent: for example, low and medium doses of the drug have a bacteriostatic effect on pathogenic microflora, and high doses have a bactericidal effect. The bacteriostatic mechanism of action of the drug is associated with inhibition of the activity of the dehydrogenase enzyme, which leads to a violation of the normal course of synthesis of vital compounds in the cell of the microorganism. Thus, due to the effect of nifuroxazide on the cell of the microorganism, there is a violation of the respiratory chain, inhibition of the tricarboxylic acid cycle. In addition, Enterofuril inhibits protein synthesis in the microbial cell and inhibits other biochemical processes in the bacterial cell. Thus, the cell of the microorganism loses its ability to reproduce.
Diarrhea of bacterial origin.
The use of Enterofuril during pregnancy is possible only in cases where the expected benefit of therapy for the mother exceeds the potential risk to the fetus.
Enterofuril is not absorbed from the gastrointestinal tract and does not enter the systemic circulation, but the use of the drug during lactation is possible only for strict indications, and the question of stopping breastfeeding should be decided.
Children under 3 years of age. hypersensitivity to nitrofuran derivatives or other components of the drug; fructose intolerance, glucose-galactose malabsorption syndrome or sucrose and isomaltase insufficiency.
Allergic reactions nausea, vomiting (anaphylactic shock, rash, urticaria, angioedema).
Inside. Nifuroxazide therapy should not be continued for more than 7 days.
Adults and children over 7 years of age are prescribed 1 capsule (200 mg) 4 times a day, the daily dose is 800 mg.
For children 3-7 years of age, the drug is prescribed 1 capsule (200 mg) 3 times a day, the daily dose is 600 mg.
The drug is not absorbed from the gastrointestinal tract and does not enter the systemic circulation.
Symptoms of overdose are not known.
If the dose is exceeded, gastric lavage and symptomatic treatment are recommended.
When treating diarrhea simultaneously with nifuroxazide therapy, rehydration therapy (oral or intravenous) should be performed according to the patient’s condition and the intensity of diarrhea.
The use of alcohol during nifuroxazide therapy is prohibited.
Before prescribing the suspension to infants, it is necessary to exclude their congenital deficiency of sucrose-breaking enzymes.
Influence on the ability to drive vehicles and work with mechanisms.
The drug does not affect psychomotor activity and the ability to drive vehicles and work with mechanisms.
Capsules
At a temperature not exceeding 30 °C
5 years
Nifuroxazide
Capsules
For adults, Children over 3 years of age, Nursing mothers as prescribed by a doctor
Intestinal Infections, Diarrhea, Salmonellosis, Poisoning
Reviews
There are no reviews yet